RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase
New York, NY – May 31, 2018- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and
Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies
Presentation Monday, June 4, 2018, at ASCO. RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional